Veneteclax binds to the BCL2 binding pocket releasing proapoptotic factors, including BIM and BAX, leading to caspase activation and malignant cell death. Continuous therapy can lead to the development of BCL2 mutations in CLL cells and clonal evolution. This may be prevented by fixed duration theory and pretreatment at relapse and progression of disease.